Degradable Cardiac Patch with Immuno-modulatory function

具有免疫调节功能的可降解心脏贴片

• 批准号: 508415-2017
• 负责人: Santerre, Paul
• 金额: $ 13.28万
• 依托单位: University of Toronto
• 依托单位国家: 加拿大
• 项目类别: Collaborative Health Research Projects
• 财政年份: 2018
• 资助国家: 加拿大
• 起止时间: 2018-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=664271
• 关键词: Degradable; Cardiac; Patch; Immuno; modulatory

Cardiovascular disease (CVD) is the leading cause of death in the world. Specifically, in 2012,**CVD was responsible for ~17.5 million deaths globally and 62,000 deaths in Canada, costing**the Canadian economy more than $21.2 billion. Myocardial infarction or heart attacks**represent the main cause of CVD-related deaths, resulting in irreversible heart muscle**damage due to the limited regenerative capacity of the heart. This can ultimately lead to endstage**heart failure, which is currently treated using heart transplantation and ventricular assist**devices (VADs). However, a shortage of donor organs as well as the high cost of VADs and**their lack of long-term suitability for all patient types are significant limitations of these**standard treatments. Tissue engineering and the development of cardiac tissue has become**a promising method for the repair and replacement of damaged myocardium and a means of**preventing end-stage heart failure. In this project, and utilizing the biomaterial expertise of**Santerre lab and the cardiovascular biology expertise of the Bendeck lab (both at the**University of Toronto) and clinical expertise of the Dr. Epelman lab at the University Hospital**network, a novel degradable polyurethane scaffold, using a biomaterial platform that has been**shown to modulate the early immune response upon implantation, will be combined with**cardiac cells, which will be derived from adipose stem cells, in order to develop a functional**and vascularized cardiac patch. The properties, performance and survival of the resulting**engineered patch will studied for their in vivo benefit.

心血管疾病（CVD）是世界上死亡的主要原因。具体而言，在2012年，** CVD在全球造成约1,750万人死亡，在加拿大造成62,000人死亡，损失了加拿大经济超过212亿加元。心肌梗死或心脏病发作**代表了与CVD相关死亡的主要原因，导致不可逆转的心肌**由于心脏再生能力有限而造成的损害。这最终可能导致终点**心力衰竭，目前使用心脏移植和心室辅助**设备（VADS）对其进行治疗。但是，缺乏供体器官以及VAD的高成本以及它们对所有患者类型的长期适合性缺乏，这是这些**标准治疗的重大局限性。组织工程和心脏组织的发展已成为**修复和更换受损心肌的有前途的方法，以及一种防止终末期心力衰竭的方法。在这个项目中，并利用了** Santerre实验室的生物材料专业知识和Bendeck Lab的心血管生物学专业知识（既在多伦多大学**大学）和Epelman博士在大学医院**网络的临床专业知识，一种新型的可降解聚氨酯支架，使用已显示的生物材料平台，该平台已被证明在植入后调节早期免疫反应，将与**心脏细胞结合使用，**心脏细胞将从脂肪干细胞中得出，以发展功能性* *和血管化心脏斑块。由此产生的**工程贴片的特性，性能和生存将为其体内利益而研究。